• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » GPOs: Lombard Medical inks supply deal with Novation

GPOs: Lombard Medical inks supply deal with Novation

June 2, 2015 By Fink Densford

lombard-medical-1x1

Lombard Medical Technologies (NSDQ:EVAR) said today that it inked a 3-year supply deal with Novation for its Aorfix endovascular stent graft.

Irving, Texas-based Novation is a group purchasing organization that serves more than 100,000 members and affiliates in the U.S., Lombard said, including VHA Inc., UHC, Children’s Hospital Assn. and Provista LLC.

"Based on a thorough review of its clinical evidence, a Novation member-led council determined that Aorfix meaningfully advances the treatment outcomes in patients with abdominal aortic aneurysms and granted its innovative technology designation to this device. We’re pleased to extend the benefits of this solution to the members we serve and who rely on Novation to provide access to the latest technologies that are clinically validated and cost-effective on contract," Novation senior clinical manager Olya Carter said in a prepared statement.

Aorfix is an endovascular stent designed to treat abdominal aortic aneurysms by creating an internal bypass of the aneurysm to reduce risk of rupture, the company said. The device is approved for indications in patients with neck angulations up to 90 degrees.

"Through this new agreement with Novation, we are able to offer more physicians in the U.S. the option to treat AAA patients with Aorfix. The designation of Innovative Technology reflects the excellent clinical outcomes demonstrated by Aorfix in the Pythagoras study and further supports our belief that Aorfix provides a safe, effective, on-label solution for a greater population of AAA patients than any other AAA stent graft," Lombard CEO Simon Hubbert said in a press release.

A post-market study of the device was launched in April this year, slated to enroll 234 patients over the next 5 years. Lombard took out a $26 million loan to use to fund the global roll-out of the Aorfix later that same month. The company won FDA approval for Aorfix in 2013.

Filed Under: Business/Financial News, Stent Grafts Tagged With: Group Purchasing Organizations (GPO), lombardmedical, Novation

More recent news

  • SS Innovations completes first robotic cardiac surgery in the Americas
  • GI Windows wins FDA nod for magnet tech
  • China reportedly launches country’s first invasive BCI trial
  • Neuralink files to raise $649M in new equity offering
  • BofA: Surgical robot remanufacturing not a major setback for Intuitive

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy